AVLOSULFON TAB 100MG DIN 00002526
Health Canada record
| Active ingredient(s) | DAPSONE 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J04BA02 DAPSONE |
| Original market date | 31-Dec-1971 |
| Current status date | 10-Sep-1996 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DAPSONE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02281074 | ACZONE | BAUSCH HEALTH, CANADA INC. | Gel | DAPSONE 5 % | Marketed |
| 02481227 | MAR-DAPSONE | MARCAN PHARMACEUTICALS INC | Tablet | DAPSONE 100 MG | Marketed |
| 02484625 | TARO-DAPSONE | TARO PHARMACEUTICALS INC | Tablet | DAPSONE 100 MG | Approved |
| 02041510 | DAPSONE | EVEREST LIFE SCIENCES LLC | Tablet | DAPSONE 100 MG | Dormant |
| 02489058 | RIVA-DAPSONE | LABORATOIRE RIVA INC. | Tablet | DAPSONE 100 MG | Dormant |
International API supply for DAPSONE
5 valid EDQM Certificates of Suitability from 5 holders. 12 active FDA Drug Master Files.
Request a quote for AVLOSULFON TAB 100MG